LIFECORE BIOMEDICAL, INC. current report, Q2 FY2014

Business Context and Reporting Period

This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a subsidiary) on June 19, 2014. The filing primarily addresses executive compensation arrangements, including a new performance bonus plan for fiscal year 2015, salary adjustments, and a new employment agreement for the CEO.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on compensation terms.

  • CEO Base Salary: Increased to $500,000 annually (effective May 26, 2014).
  • Other Executive Salary: Molly Hemmeter's salary increased to $345,000 (effective May 26, 2014).
  • Bonus Structure (Fiscal 2015):
    • Executive officers: 40% to 100% of base salary.
    • Other employees: 9% to 40% of base salary.
    • Performance targets: Revenue and controllable net income must exceed specified targets.

Material Changes

The following material changes were approved by the Board of Directors on June 19, 2014:

  • Compensation Plan: Adoption of a cash bonus plan for Landec, Apio, Inc., and Lifecore Biomedical, Inc. employees for fiscal year 2015.
  • Salary Increases: Retroactive salary increases for Gary Steele (CEO) and Molly Hemmeter effective May 26, 2014.
  • Employment Agreement: Execution of a new agreement with CEO Gary T. Steele, effective May 26, 2014, expiring May 29, 2016.
  • Clawback Policy: Adoption of a policy allowing recoupment of executive incentive compensation in the event of financial restatements due to material noncompliance.

Outlook, Risks, and Contingencies

Severance and Change of Control Provisions:

  • Termination without cause/Good reason: 100% of annual base salary plus one-year acceleration of unvested equity and lifetime Medicare premium reimbursement for the CEO and spouse.
  • Change of Control (within 2 years): 150% of annual base salary plus lifetime Medicare premium reimbursement. All unvested equity awards immediately vest.
  • Death/Disability: Payment of unpaid base salary and pro rata incentive award.

Risks and Contingencies:

  • Clawback Risk: The new policy exposes executive incentive compensation to recovery if financial results are restated due to material noncompliance within three years of the restatement date (post-May 27, 2013).
  • Non-Compete/Non-Solicit: The CEO is restricted from soliciting employees, consultants, licensors, or customers for two years post-termination.

Investor Verification Checklist

  • Verify the exact terms of the Employment Agreement (Exhibit 10.40) regarding the definition of "good reason" and "change of control."
  • Confirm the specific revenue and controllable net income targets for fiscal year 2015 required to trigger the bonus plan, as these are not detailed in the summary text.
  • Review the Clawback Policy details to understand the threshold for "substantial restatement" and the Board's discretion in recovery.
  • Check subsequent filings for the actual vesting status of equity awards and any future amendments to the compensation plan.